Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC

NCT01620944 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

3

Enrollment

INDUSTRY

Sponsor class

Stopped Business objectives have changed

Conditions

HIV

Interventions

DRUG: Atazanavir
DRUG: Ritonavir
DRUG: Lamivudine
DRUG: Tenofovir/Emtricitabine

Sponsor

Bristol-Myers Squibb